Skip to content

Pharvaris

US · PHVS #2729 by market cap Listed 2021
31.28 -0.38 -1.20%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Recent news

  • Morgan Stanley Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $62
    Market Newswire · 2026/11/9
  • Rating change
    H.C. Wainwright Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $60
    Market Newswire · 2026/10/6
  • Rating change
    Morgan Stanley Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $41
    Market Newswire · 2026/6/15
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Fractyl Health, Inc. (GUTS) and Ascendis Pharma (ASND)
    TipRanks · 2026/10/19
  • Earnings Flash (PHVS) Pharvaris Posts Q3 Loss 0.67 Euros a Share, Vs. FactSet Est of 0.77 Euro Loss
    MT Newswires · 2026/11/12
  • Rating change
    BofA Securities Maintains Pharvaris(PHVS.US) With Hold Rating, Raises Target Price to $35
    Market Newswire · 2026/7/29
  • Oppenheimer Initiates Pharvaris(PHVS.US) With Buy Rating, Announces Target Price $75
    Market Newswire · 2026/11/13
  • Rating change
    Morgan Stanley Maintains Pharvaris(PHVS.US) With Buy Rating, Raises Target Price to $46
    Market Newswire · 2026/6/25
  • Rating change
    Morgan Stanley Maintains Pharvaris(PHVS.US) With Buy Rating, Cuts Target Price to $30.4
    Market Newswire · 2026/5/18
  • Rating change
    A Quick Look at Today's Ratings for Pharvaris(PHVS.US), With a Forecast Between $38 to $55
    Market Newswire · 2026/8/13
  • Wells Fargo Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $65
    Market Newswire · 2026/11/13
  • Rating change
    A Quick Look at Today's Ratings for Pharvaris(PHVS.US), With a Forecast Between $44 to $79
    Market Newswire · 2026/9/10
  • Rating change
    BofA Securities Upgrades Pharvaris(PHVS.US) to Buy Rating, Maintains Target Price $44
    Market Newswire · 2026/10/23
  • Rating change
    JonesTrading Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $52
    Market Newswire · 2026/8/29
  • Rating change
    Pharvaris (PHVS) Gets a Buy From H.C. Wainwright
    TipRanks · 2026/9/22
  • Rating change
    Oppenheimer Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $50
    Market Newswire · 2026/5/13
  • Rating change
    BofA Securities Maintains Pharvaris(PHVS.US) With Hold Rating, Raises Target Price to $33
    Market Newswire · 2026/5/14
  • Rating change
    Wells Fargo Initiates Pharvaris(PHVS.US) With Buy Rating, Announces Target Price $55
    Market Newswire · 2026/7/15
  • RBC Capital Maintains Pharvaris(PHVS.US) With Buy Rating, Raises Target Price to $63
    Market Newswire · 2026/11/14
  • Rating change
    Morgan Stanley Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $46
    Market Newswire · 2026/9/8
  • Rating change
    A Quick Look at Today's Ratings for Pharvaris(PHVS.US), With a Forecast Between $46 to $74
    Market Newswire · 2026/5/13
  • Wells Fargo Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $65
    Market Newswire · 2026/10/15
  • Morgan Stanley Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $62
    Market Newswire · 2026/10/26
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), BioAge Labs, Inc. (BIOA) and Pharvaris (PHVS)
    TipRanks · 2026/5/10
  • Rating change
    Wedbush Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $42
    Market Newswire · 2026/5/13

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:01:10 · For reference only, not investment advice and not tailored to your situation.

Pharvaris discussion 0 comments

Add a comment